BACKGROUND: We investigated the efficacy of everolimus against nonclear-cell renal cell carcinoma (nccRCC). Patients and methods Patients with nccRCC received 10-mg everolimus once daily until disease progression or unacceptable toxicity. PATIENTS: who had received a VEGF- tyrosine kinase inhibitor (TKI) previously were included. RESULTS: A total of 49 patients were enrolled. Twenty-three patients (46.9%) received prior anti-VEGF agents. A partial response was observed in five patients (10.2%) and stable disease in 25 patients (51.0%). The disease progressed in 16 patients (32.7%) despite the administration of everolimus. Two of the five patients who showed an objective response to everolimus had chromophobe carcinoma, whereas two had papillary carcinoma and one had unclassifiable carcinoma. Thirty-six patients experienced disease progression during follow-up, and the median progression-free survival (PFS) was 5.2 months. Chromophobe RCC patients seemed to have longer PFS than nccRCC patients with the other histological subtypes (P = 0.084). Previous VEGF-TKI treatment did not influence the efficacy of everolimus, and the toxicity profiles were in line with previous reports. CONCLUSION: Everolimus shows certain efficacy against nccRCC, particularly in patients with chromophobe RCC, and prior treatment with a VEGF-TKI appears not influencing the outcome of everolimus therapy in nccRCC patients. ClinicalTrials.gov number NCT00830895.
BACKGROUND: We investigated the efficacy of everolimus against nonclear-cell renal cell carcinoma (nccRCC). Patients and methods Patients with nccRCC received 10-mg everolimus once daily until disease progression or unacceptable toxicity. PATIENTS: who had received a VEGF- tyrosine kinase inhibitor (TKI) previously were included. RESULTS: A total of 49 patients were enrolled. Twenty-three patients (46.9%) received prior anti-VEGF agents. A partial response was observed in five patients (10.2%) and stable disease in 25 patients (51.0%). The disease progressed in 16 patients (32.7%) despite the administration of everolimus. Two of the five patients who showed an objective response to everolimus had chromophobe carcinoma, whereas two had papillary carcinoma and one had unclassifiable carcinoma. Thirty-six patients experienced disease progression during follow-up, and the median progression-free survival (PFS) was 5.2 months. Chromophobe RCCpatients seemed to have longer PFS than nccRCC patients with the other histological subtypes (P = 0.084). Previous VEGF-TKI treatment did not influence the efficacy of everolimus, and the toxicity profiles were in line with previous reports. CONCLUSION:Everolimus shows certain efficacy against nccRCC, particularly in patients with chromophobe RCC, and prior treatment with a VEGF-TKI appears not influencing the outcome of everolimus therapy in nccRCC patients. ClinicalTrials.gov number NCT00830895.
Authors: Andrew J Armstrong; Susan Halabi; Tim Eisen; Samuel Broderick; Walter M Stadler; Robert J Jones; Jorge A Garcia; Ulka N Vaishampayan; Joel Picus; Robert E Hawkins; John D Hainsworth; Christian K Kollmannsberger; Theodore F Logan; Igor Puzanov; Lisa M Pickering; Christopher W Ryan; Andrew Protheroe; Christine M Lusk; Sadie Oberg; Daniel J George Journal: Lancet Oncol Date: 2016-01-13 Impact factor: 41.316
Authors: M H Voss; D A Bastos; C A Karlo; A Ajeti; A A Hakimi; D R Feldman; J J Hsieh; A M Molina; S Patil; R J Motzer Journal: Ann Oncol Date: 2014-01-23 Impact factor: 32.976
Authors: Martin H Voss; Ana M Molina; Ying-Bei Chen; Kaitlin M Woo; Joshua L Chaim; Devyn T Coskey; Almedina Redzematovic; Patricia Wang; William Lee; S Duygu Selcuklu; Chung-Han Lee; Michael F Berger; Satish K Tickoo; Victor E Reuter; Sujata Patil; James J Hsieh; Robert J Motzer; Darren R Feldman Journal: J Clin Oncol Date: 2016-11-10 Impact factor: 44.544
Authors: Nizar M Tannir; Eric Jonasch; Laurence Albiges; Emre Altinmakas; Chaan S Ng; Surena F Matin; Xuemei Wang; Wei Qiao; Zita Dubauskas Lim; Pheroze Tamboli; Priya Rao; Kanishka Sircar; Jose A Karam; David F McDermott; Christopher G Wood; Toni K Choueiri Journal: Eur Urol Date: 2015-11-26 Impact factor: 20.096
Authors: Lauren C Harshman; Nils Kroeger; Sun Young Rha; Frede Donskov; Lori Wood; Srinivas K Tantravahi; Ulka Vaishampayan; Brian I Rini; Jennifer Knox; Scott North; Scott Ernst; Takeshi Yuasa; Sandy Srinivas; Sumanta Pal; Daniel Y Heng; Toni K Choueiri Journal: Clin Genitourin Cancer Date: 2014-03-15 Impact factor: 2.872
Authors: Chung-Han Lee; Martin H Voss; Maria Isabel Carlo; Ying-Bei Chen; Mark Zucker; Andrea Knezevic; Robert A Lefkowitz; Natalie Shapnik; Chloe Dadoun; Ed Reznik; Neil J Shah; Colette Ngozi Owens; Deaglan Joseph McHugh; David Henry Aggen; Andrew Leonard Laccetti; Ritesh Kotecha; Darren R Feldman; Robert J Motzer Journal: J Clin Oncol Date: 2022-03-17 Impact factor: 50.717
Authors: Nils Kroeger; Wanling Xie; Jae-Lyn Lee; Georg A Bjarnason; Jennifer J Knox; Mary J Mackenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishamayan; Sun-Young Rha; Sumanta K Pal; Takeshi Yuasa; Frede Donskov; Neeraj Agarwal; Christian K Kollmannsberger; Min-Han Tan; Scott A North; Brian I Rini; Toni K Choueiri; Daniel Y C Heng Journal: Cancer Date: 2013-05-21 Impact factor: 6.860
Authors: Darren R Feldman; Yasser Ged; Chung-Han Lee; Andrea Knezevic; Ana M Molina; Ying-Bei Chen; Joshua Chaim; Devyn T Coskey; Samuel Murray; Satish K Tickoo; Victor E Reuter; Sujata Patil; Han Xiao; Jahan Aghalar; Arlyn J Apollo; Maria I Carlo; Robert J Motzer; Martin H Voss Journal: Cancer Date: 2020-09-25 Impact factor: 6.860